$1.5 million for adult stem cell research in Australia

Australian adult stem cell company, Mesoblast Limited, today announced that its chief scientific advisor and founder, Professor Silviu Itescu, has been awarded a $1.5 million grant for pre-clinical and clinical development of mesenchymal lineage adult stem cells.

The grant was awarded under the prestigious National Health and Medical Research Council’s Program Grants Scheme, with the $1.5 million allocation being made under a specific Memorandum of Understanding.

Professor Itescu said he was delighted with the Australian Government’s endorsement and its support for the development of adult stem cells as novel therapeutic strategies in patients.

“The grant will be instrumental in sponsoring a number of clinical and preclinical studies using mesenchymal lineage adult stem cells”, he said.

“There is enormous interest within the international medical community in the potential of adult stem cells to provide effective treatments for a broad range of human diseases and conditions and to vastly improve the quality of life for many people.

“Additionally, these therapies may result in significant reductions to ballooning health care costs”, Professor Itescu said.

The Chairman of Mesoblast, Mr Michael Spooner, indicated that subject to material transfer agreements, Mesoblast would make available its specialist Mesenchymal Precursor Cells for these and other Government and industrysponsored studies.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer